Regression model | Adjusted R2 | Significant variables | β coefficient | p Value |
---|---|---|---|---|
Primary model (age, sex, symptom duration, duration of follow-up, BL CRP, BL mSASSS, treatment) | 0.054 | Age | 0.011 | <0.001 |
Duration of follow-up | 0.004 | 0.03 | ||
CRP | 0.005 | 0.03 | ||
Primary model plus SSS fat metaplasia score | 0.14 | Age | 0.011 | 0.002 |
Duration of follow-up | 0.010 | 0.002 | ||
Fat metaplasia | 0.027 | <0.001 | ||
Primary model plus SSS erosion score | 0.10 | Age | 0.015 | <0.001 |
CRP | 0.006 | 0.02 | ||
Duration of follow-up | 0.011 | 0.002 | ||
Primary model plus SSS backfill score | 0.10 | Age | 0.015 | <0.001 |
CRP | 0.006 | 0.016 | ||
Duration of follow-up | 0.011 | 0.002 | ||
Primary model plus SSS ankylosis score | 0.10 | Age | 0.015 | <0.001 |
CRP | 0.006 | 0.018 | ||
Duration of follow-up | 0.011 | 0.002 | ||
Primary model plus SSS fat metaplasia, erosion, backfill, ankylosis scores | 0.15 | Age | 0.010 | 0.01 |
Duration of follow-up | 0.011 | 0.001 | ||
Fat metaplasia | 0.025 | 0.001 | ||
Ankylosis | 0.012 | 0.047 |
BL CRP, Basile C-reactive protein; FORCAST, Follow Up Research Cohort in Ankylosing Spondylitis; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; SpA, spondyloarthritis; SPARCC, Spondyloarthritis Research Consortium of Canada; SSS, SPARCC MRI SIJ Structural Scoring.